Floatz logo

METHOTREXATE

Peritoneal Cavity Cancer

Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Peritoneal Cavity Cancer cohort.

Asset / SponsorPhaseRating
PEGFILGRASTIM
TORL Biotherapeutics, LLC
Phase 2/3BBB
Inno-206
Case Comprehensive Cancer Center
Phase 3BBB
Sargramostim
Barbara Ann Karmanos Cancer Institute
Phase 2BB
Ixabepilone
Yale University
Phase 2BB
FLUTICASONE
Barbara Ann Karmanos Cancer Institute
Phase 2BB

View all 24 →

Same molecule, other indications

METHOTREXATE is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute promyelocytic leukemiaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →